The PTAB (Patent Trial and Appeal Board) has declared that Daiichi Sankyo successfully demonstrated that the disputed claims of a Seagen cancer drug patent, for which it was found guilty of infringement in a $42 million verdict delivered by a Texas federal jury in 2022, were invalid.
The PTAB’s assessment casts a cloud of uncertainty on Seagen’s intellectual property rights pertaining to its cancer drug, bringing a fresh twist in this convoluted legal saga.
The rigorous process of the patent validation involves dissection of the patent claims and an in-depth analysis of their novelty, inventiveness, and industrial utility as all these factors contribute to the legitimacy of a patent.
Although the jury had previously ruled in favor of Seagen, the PTAB’s recent decision could potentially undermine the credibility of the initial trial verdict. However, due to the multi-dimensional aspects involved in such litigation, ongoing appeal processes might allow for future course alterations in this case.
Corporate legal stakeholders, patent attorneys, and IP strategists will undoubtedly track this and related cases, owing to their potential implications on the broader domain of pharmaceutical Intellectual Property rights.
While both Daiichi Sankyo and Seagen are yet to comment on the PTAB’s latest ruling, a thorough coverage of the developments can be found here.